First, the biosynthesis of 11-oxo-ETE was conducted using11(R)-HE

First, the biosynthesis of 11-oxo-ETE was conducted using11(R)-HETE and recombinant 15-PGDH [20]. The catalytic activity of 15-PGDH was approximately one-third that for 15(S)-HETE but nevertheless, it efficiently produced the corresponding 11-oxo-ETE. This result was quite unexpected, since 11(R)-HETE lacks the 15(S)-hydroxyl group that is normally required by the 15-PGDH enzyme. The identity Inhibitors,research,lifescience,medical of the newly formed 11-oxo-ETE was established by comparison with an authentic standard. The product of the 15-PGDH catalyzed reaction of 11(R)-HETE had the same MS/MS spectrum as an

authentic standard and the same chromatographic properties [20]. The LoVo cell line was used to assess the formation of 11-oxo-ETE in vivo. LoVo cells are human colorectal carcinoma cells and are expressing both COX-2 and 15-PGDH [20]. When the cells were incubated with 11(R)-HETE in presence of NAD+, the chiral targeted lipidomics profile Inhibitors,research,lifescience,medical showed the presence of 11-oxo-ETE, with same LC-MS characteristics as a synthetic standard. LC-MS analysis showed that 11-oxo-ETE was formed in similar amounts to 15-oxo-ETE. 11-oxo-ETE and 15-oxo-ETE share a common product ion at m/z 165, since this ion results from the cleavage of the bond between Inhibitors,research,lifescience,medical C-9 and C10, so it was necessary

that the two oxo-ETEs to be well separated by the chromatographic run (15-oxo-ETE had a retention time of 12.0 min and 11-oxo-ETE had a retention time of 12.8 min) (Figure 4). 15-oxo-ETE was also produced (Figure 4) but in lower amount, and the 13,14-dihydro-15-oxo-PGE2 was an order of magnitude lower than the 11-oxo-ETE. Figure 4 Targeted chiral lipidomics analysis of COX-2-derived eicosanoids from LoVo cells. Inhibitors,research,lifescience,medical LoVo cells were lysed; eicosanoids were extracted, PRT062607 manufacturer derivatized with PFB bromide, and analyzed by LC-ECAPCI/SRM/MS. LoVo cell lysates were pretreated with 50 μM … Similar experiments were performed with the HCA-7 cells, a human

colonic adenocarcinoma line [110]. The HCA-7 cells just have trace amounts of 15-PGDH [114,120] Inhibitors,research,lifescience,medical even though COX-2 is expressed at high levels. “type”:”entrez-protein”,”attrs”:”text”:”CAY10397″,”term_id”:”290784407″,”term_text”:”CAY10397″CAY10397, a 15-PGDH inhibitor, was used to examine its effect on oxidized eicosanoid formation. In the LoVo cells, the concentrations of 11-oxo-ETE, 15-oxo-ETE, (-)-p-Bromotetramisole Oxalate and 13,14-dihydro-15-oxo-PGE2 were drastically reduced. In contrast, HCA-7 cells, which do not express 15-PGDH, showed no decrease in the levels of 15(S)-HETE and PGE2. In the LoVo cells, both 11-oxo-ETE and 15-oxo-ETE reached a maximum concentration at approximately 10 min and then decreased to a steady state concentration over 2.5 h. Due to the rapid clearance of the 11-oxo-ETE in the LoVo cells, its metabolic fate was further investigated.

Leave a Reply

Your email address will not be published. Required fields are marked *

*

You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>